摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氨基-6-溴苯酚 | 28165-50-6

中文名称
2-氨基-6-溴苯酚
中文别名
——
英文名称
2-amino-6-bromophenol
英文别名
2-bromo-6-aminophenol;2-hydroxy-3-bromoaniline
2-氨基-6-溴苯酚化学式
CAS
28165-50-6
化学式
C6H6BrNO
mdl
——
分子量
188.024
InChiKey
LOBRHADLNRMHOO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    83-84°C
  • 沸点:
    246.4±25.0 °C(Predicted)
  • 密度:
    1.768±0.06 g/cm3(Predicted)
  • pKa:
    8.22±0.10 (Predicted,Most Acidic Temp: 25 °C)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    46.2
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S60,S61
  • 危险类别码:
    R22,R50/53
  • 海关编码:
    2922299090
  • WGK Germany:
    3
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    | 温度范围:2-8℃ |

SDS

SDS:7f22ac89b253564281a782e00f031652
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Amino-6-bromophenol
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H410: Very toxic to aquatic life with long lasting effects
P273: Avoid release to the environment

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-6-bromophenol
CAS number: 28165-50-6

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H6BrNO
Molecular weight: 188

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氨基-6-溴苯酚 在 palladium diacetate 、 caesium carbonate 、 potassium hydroxide 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 25.0h, 生成 3'-氨基-2'-羟基-[1,1'-联苯]-3-甲酸
    参考文献:
    名称:
    一种合成艾曲波帕中间体3’-氨基-2’-羟基联苯-3-羧酸的方法
    摘要:
    本发明公开了一种合成艾曲波帕关键中间体3’‑氨基‑2’‑羟基联苯‑3‑羧酸的方法,以2‑溴‑6‑硝基苯酚为原料,经过硝基还原、环化保护、Suzuki偶联和水解脱保护四步反应得到目标产物。本发明中的硝基还原步骤原料廉价易得,使用的氢源操作便捷、安全;环化保护步骤使用杂多酸类离子液体催化剂合成方法简易、高活性、可多次回收套用、绿色环保;Suzuki偶联步骤采用价格低、来源广泛易得的钯碳为催化剂,简单过滤分离后可以直接回收套用;水解脱保护步骤操作简单、转化率高。
    公开号:
    CN115322110A
  • 作为产物:
    描述:
    2-溴-6-硝基苯酚铁粉溶剂黄146 作用下, 反应 0.5h, 以83%的产率得到2-氨基-6-溴苯酚
    参考文献:
    名称:
    新型苯并恶唑酮衍生物作为18 kDa转运蛋白(TSPO)配体的设计,合成和结构-活性关系
    摘要:
    选择性的18 kDa转运蛋白(TSPO)配体有望成为对精神疾病具有广泛作用且副作用较少的治疗剂。我们设计了新颖的苯并恶唑酮衍生物,并研究了在酰胺部分和C-5位置具有多个取代基的一系列化合物的结构-活性关系(SAR)。尽管许多合成的化合物显示出高的TSPO结合亲和力,但这些化合物的药物样性质较差。这些化合物的药代动力学特性的进一步优化导致发现化合物74,该化合物在大鼠Vogel冲突模型中表现出抗焦虑作用。
    DOI:
    10.1016/j.bmc.2012.07.023
点击查看最新优质反应信息

文献信息

  • [EN] CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF<br/>[FR] MODULATEURS DE CALPAÏNE ET LEURS UTILISATIONS THÉRAPEUTIQUES
    申请人:BLADE THERAPEUTICS INC
    公开号:WO2019190885A1
    公开(公告)日:2019-10-03
    Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.
    小分子钙蛋白酶调节剂化合物,包括其药用可接受的盐,可以包含在药物组合物中。这些化合物可以通过与主体内的CAPN1、CAPN2和/或CAPN9酶接触来抑制钙蛋白酶,或与蛋白酶抑制剂竞争性结合。这些化合物和组合物也可以被用于治疗纤维化疾病或纤维化疾病的继发疾病状态或病情。
  • IRAK DEGRADERS AND USES THEREOF
    申请人:Kymera Therapeutics, Inc.
    公开号:US20190192668A1
    公开(公告)日:2019-06-27
    The present invention provides compounds, compositions thereof, and methods of using the same.
    本发明提供了化合物、其组合物以及使用这些化合物的方法。
  • [EN] PIKFYVE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE PIKFYVE
    申请人:ACURASTEM INCORPORATED
    公开号:WO2021163727A1
    公开(公告)日:2021-08-19
    The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.
    本发明涉及作为磷脂酰肌醇-3-磷酸5-激酶(PIKfyve)抑制剂的化合物,以及它们用于治疗与PIKfyve相关的疾病和紊乱的用途。
  • N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
    申请人:Rodgers James D.
    公开号:US20100298334A1
    公开(公告)日:2010-11-25
    The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及式I的N-(杂)芳基吡咯烷衍生物: 这些是JAK抑制剂,如选择性JAK1抑制剂,在治疗JAK相关疾病方面具有用处,例如炎症和自身免疫性疾病,以及癌症。
  • [EN] BENZOXAZINE DERIVATIVES AS GLYCINE TRANSPORT INHIBITORS<br/>[FR] DÉRIVÉS DE BENZOXAZINE INHIBITEURS DU TRANSPORT DE GLYCINE
    申请人:GLAXO GROUP LTD
    公开号:WO2011023753A1
    公开(公告)日:2011-03-03
    The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by Gly T1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.
    本发明涉及苯并恶嗪酮衍生物、它们的制备方法、含有它们的药物组合物和药物,以及它们在治疗由GlyT1介导的疾病中的应用,包括神经和精神疾病,特别是精神病、痴呆或注意力缺陷障碍。
查看更多